ALS Limited (ASX:ALQ): FY26 Earnings Growth, Lower Debt and FY27 Priorities

Aditi Sarkar

01 October 2026 11:52 PM AEST

ALS Limited (ASX:ALQ): FY26 Earnings Growth, Lower Debt and FY27 Priorities

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 Revenue reached A$3,320.1 million and underlying NPAT increased to A$381.2 million.
Commodities recorded faster growth as mineral exploration activity supported sample volumes.
Group underlying EBIT Margin increased to 18.0%.
Free Cash Flow rose to A$674.1 million and net Debt declined to A$1,069.5 million.
FY27 priorities centre on organic growth, margin development and laboratory capacity.

ALS Limited (ASX:ALQ) is a global testing Business providing analytical and technical services across mining, environmental, food and pharmaceutical markets. The company describes its role as using testing and data-driven insights to help clients address operational, quality and safety challenges. Its FY26 result for the year ended 31 March 2026 showed higher revenue, Earnings and cash generation together with lower net debt. The result also showed different growth rates across Commodities and Life Sciences, which remains important to the FY27 outlook.

FY26 Financial Performance

Revenue increased 10.7% to A$3,320.1 million. Underlying EBIT rose 19.3% to A$599.0 million and the underlying EBIT margin increased by 129 basis points to 18.0%. Underlying NPAT reached A$381.2 million, up 25.8%, while statutory NPAT was A$318.7 million, up 24.4%. Basic Earnings Per Share were 75.7 cents. The difference between underlying and statutory profit reflects items excluded from the company’s underlying presentation.

Commodities Drove the Faster Growth

Commodities revenue increased 18.8% to A$1,294.2 million and underlying EBIT rose 25.9% to A$381.5 million. Its EBIT margin reached 29.5%. ALS linked the performance to increased mineral exploration activity, higher testing volumes and improved pricing. Minerals organic revenue increased 20.2%, while Geochemistry organic revenue rose 22.7%. Earlier Investment in laboratory capacity helped the division process higher sample volumes as client activity increased.

Life Sciences Broadened the Earnings Base

Life Sciences revenue increased 6.0% to A$2,025.9 million, with underlying EBIT up 10.2% to A$296.5 million and a margin of 14.6%. Food testing recorded organic revenue growth of 7.2%, while Environmental experienced softer conditions in parts of the Americas. ALS also completed its two-year Nuvisan transformation program during FY26, with an exit run rate of about EUR25 million in cost reductions. Life Sciences gives the group exposure to testing Demand linked to regulation, product quality and health-related markets.

Cash Flow, Debt and Capital Allocation

Free cash flow increased 14.1% to A$674.1 million, while net debt fell to A$1,069.5 million from A$1,424.1 million. Underlying return on capital employed increased to 21.5%. The total Dividend was 42.5 cents per share, representing 57% of underlying NPAT. Capital Expenditure was A$263 million, including investment in laboratory capacity and hub projects. The lower debt position gives ALS more flexibility as it balances network investment with Shareholder distributions.

FY27 Priorities and Operating Factors

Management is targeting mid- to high-single-digit organic revenue growth in FY27, with further margin development broadly consistent with FY26. Minerals organic revenue growth is targeted at 13% to 15% for the year, while Life Sciences is expected to deliver improved mid-single-digit growth. ALS also identified a possible foreign-exchange headwind of A$3 million to A$10 million on annual earnings. Delivery will depend on customer activity, laboratory utilisation, pricing and currency movements.

Key Insights

ALS entered FY27 with higher earnings, wider margins and lower net debt. Commodities remains the faster-moving part of the portfolio because its activity responds to mineral exploration and project development, while Life Sciences provides a broader base across regulated testing markets. Key measures for the next reporting periods include Minerals growth, Life Sciences momentum, margin progression and whether continued laboratory investment can support growth without weakening cash conversion.

FAQs

Q: What does ALS Limited do?

A:ALS provides testing, analytical and technical services across mining, environmental, food, pharmaceutical and other industries.

Q: What was ALS Limited’s FY26 revenue?

A:ALS reported FY26 revenue of A$3,320.1 million for the year ended 31 March 2026.

Q: Which ALS division grew faster in FY26?

A:Commodities recorded the faster revenue and EBIT growth, supported by increased mineral exploration and testing activity.

Q: How much net debt did ALS report at the end of FY26?

A:Net debt was A$1,069.5 million at 31 March 2026.

Q: What is ALS targeting for FY27?

A:Management is targeting mid- to high-single-digit organic revenue growth, including Minerals growth of 13% to 15%.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.